


What is claimed is:

1. A compound of the formula



wherein

R<sub>1</sub> is -CH<sub>2</sub>-X, -O-X or -S(O)<sub>0-2</sub>-X; or

R<sub>1</sub> is -NR<sub>8</sub>-X, -NR<sub>8</sub>C(O)-X or -NR<sub>8</sub>S(O)<sub>2</sub>-X in which

R<sub>8</sub> is hydrogen or lower alkyl; and

X is -(CH<sub>2</sub>)<sub>m</sub>-(CR<sub>9</sub>R<sub>10</sub>)<sub>p</sub>-(CH<sub>2</sub>)<sub>n</sub>-Z-(CH<sub>2</sub>)<sub>q</sub>-W in which

m, n and q are independently zero or an integer from 1 to 5;

p is zero or 1;

R<sub>9</sub> and R<sub>10</sub> are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or

R<sub>9</sub> and R<sub>10</sub> combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;

Z is a bond; or

Z is O, S(O)<sub>0-2</sub>, or -NR<sub>11</sub>- in which

R<sub>11</sub> is hydrogen or lower alkyl, provided that R<sub>1</sub> is -CH<sub>2</sub>-X when m, n and p are all zero;

W is aryl or heterocyclyl;

R<sub>2</sub> is hydrogen, halogen, cyano, hydroxy or lower alkoxy;

L is a bond; or

L is -(CH<sub>2</sub>)<sub>s</sub>-O-(CH<sub>2</sub>)<sub>v</sub>- in which

s and v are independently zero or an integer from 1 to 3; or

- 77 -

L is  $-C(O)-$ ,  $-C(O)O-$ ,  $-OC(O)-$ ,  $-OC(O)NR_{12}-$ ,  $-NR_{12}-$ ,  $-NR_{13}C(O)-$ ,  $-NR_{13}C(O)O-$  or  $-NR_{13}C(O)NR_{12}-$  in which

$R_{12}$  and  $R_{13}$  are independently hydrogen or lower alkyl;

$R_3$  is hydrogen, hydroxy, halogen or cyano provided that L is a bond; or

$R_3$  is optionally substituted lower alkyl, aralkyl, heteroaralkyl, aryl or heterocyclyl; or

$R_3$  and  $R_{12}$  combined are alkylene which together with the nitrogen atom to which they are attached form a 5- to 6-membered ring;

$R_4$  is hydrogen, optionally substituted lower alkyl or aryl;

$R_5$  and  $R_6$  are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

$R_5$  and  $R_6$  combined together with the carbon atoms to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided that  $R_5$  and  $R_6$  are attached to carbon atoms adjacent to each other; or

$R_5$  and  $R_6$  combined are alkylene which together with the carbon atoms to which they are attached form a fused 5- to 7-membered ring provided that  $R_5$  and  $R_6$  are attached to carbon atoms adjacent to each other; or

C- $R_5$  and C- $R_6$  may be replaced with nitrogen;

$R_7$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy, cycloalkyl, alkanoyl, alkyloxyalkoxy, alkanoyloxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, carboxy, alkoxycarbonyl, aryl, alkenyl, alkynyl, aralkoxy, heterocyclyl including indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl, piperidyl, morpholinyl and tetrazolyl; or

$R_7$  and  $R_6$  combined are O,  $S(O)_{0-2}$ ,  $-NR_{14}-$ ,  $-(CH_2)_{1-2}-$ ,  $-O-CH_2-$ ,  $-CH_2-O-$ ,  $-S(O)_{0-2}-CH_2-$ ,  $-CH_2-S(O)_{0-2}-$ ,  $-NR_{14}-CH_2-$ ,  $-CH_2-NR_{14}-$ ,  $-S(O)_{0-2}-NR_{14}-$  or  $-NR_{14}-S(O)_{0-2}-$  in which

$R_{14}$  is hydrogen or lower alkyl, provided  $R_6$  is located at the 2' position; or

C- $R_7$  may be replaced with nitrogen;

Y is  $-(CH_2)_r-$ ,  $-O-(CH_2)_r-$ ,  $-(CH_2)_rO-$ ,  $-S_{0-2}-(CH_2)_r-$  or  $-(CH_2)_rS_{0-2}-$  in which

r is zero or an integer from 1 to 3;

Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or

Q combined with the atoms to which it is attached form a 7- to 12-membered bicyclic aromatic or heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1 wherein

$R_1$  is  $-\text{CH}_2\text{-X}$ ,  $-\text{O-X}$  or  $-\text{S(O)}_{0-2}\text{-X}$ ; or

$R_1$  is  $-\text{NR}_8\text{-X}$ ,  $-\text{NR}_8\text{C(O)-X}$  or  $-\text{NR}_8\text{S(O)}_2\text{-X}$  in which

$R_8$  is hydrogen or lower alkyl; and

X is  $-(\text{CH}_2)_m\text{-(CR}_9\text{R}_{10})_p\text{-(CH}_2)_n\text{-Z-(CH}_2)_q\text{-W}$  in which

m and n are independently zero or an integer from 1 to 5;

p is zero or 1;

q is zero;

$R_9$  and  $R_{10}$  are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or

$R_9$  and  $R_{10}$  combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;

Z is a bond; or

Z is O,  $\text{S(O)}_{0-2}$ , or  $-\text{NR}_{11}-$  in which

$R_{11}$  is hydrogen or lower alkyl, provided that  $R_1$  is  $-\text{CH}_2\text{-X}$  when m, n and p are all zero;

W is aryl or heterocyclyl;

$R_2$  is hydrogen, halogen, cyano, hydroxy or lower alkoxy;

L is a bond; or

L is  $-(\text{CH}_2)_s\text{-O-(CH}_2)_v\text{-}$  in which

s and v are zero; or

L is  $-\text{C(O)-}$ ,  $-\text{C(O)O-}$ ,  $-\text{OC(O)-}$ ,  $-\text{OC(O)NR}_{12}\text{-}$ ,  $-\text{NR}_{12}\text{-}$ ,  $-\text{NR}_{13}\text{C(O)-}$ ,  $-\text{NR}_{13}\text{C(O)O-}$  or  $-\text{NR}_{13}\text{C(O)NR}_{12}\text{-}$  in which

$R_{12}$  and  $R_{13}$  are independently hydrogen or lower alkyl;

- 79 -

R<sub>3</sub> is hydrogen, halogen or cyano provided that L is a bond; or

R<sub>3</sub> is optionally substituted lower alkyl, aralkyl, heteroaralkyl, aryl or heterocyclyl; or

R<sub>3</sub> and R<sub>12</sub> combined are alkylene which together with the nitrogen atom to which they are attached form a 5- to 6-membered ring;

R<sub>4</sub> is hydrogen, optionally substituted lower alkyl or aryl;

R<sub>5</sub> and R<sub>6</sub> are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

R<sub>5</sub> and R<sub>6</sub> combined together with the carbon atoms to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided that R<sub>5</sub> and R<sub>6</sub> are attached to carbon atoms adjacent to each other; or

R<sub>5</sub> and R<sub>6</sub> combined are alkylene which together with the carbon atoms to which they are attached form a fused 5- to 7-membered ring provided that R<sub>5</sub> and R<sub>6</sub> are attached to carbon atoms adjacent to each other; or

R<sub>7</sub> is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted, lower alkyl, lower alkoxy or cycloalkyl; or

R<sub>7</sub> and R<sub>8</sub> combined are O, S(O)<sub>0-2</sub>, -NR<sub>14</sub>-, -(CH<sub>2</sub>)<sub>1-2</sub>-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-, -S(O)<sub>0-2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-S(O)<sub>0-2</sub>-, -NR<sub>14</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-NR<sub>14</sub>-, -S(O)<sub>0-2</sub>-NR<sub>14</sub>- or -NR<sub>14</sub>-S(O)<sub>0-2</sub>- in which

R<sub>14</sub> is hydrogen or lower alkyl, provided R<sub>8</sub> is located at the 2' position;

Y is -(CH<sub>2</sub>)<sub>r</sub>- in which


r is zero;

Q combined with the carbon atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or

Q combined with the carbon atoms to which it is attached form a 9- to 10-membered bicyclic aromatic or heterocyclic ring;

or a pharmaceutically acceptable salt thereof.


3. A compound according to Claim 2 of the formula



wherein

$R_1$ ,  $R_2$ ,  $L$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$  and  $Q$  have meanings as defined in Claim 2;  
or a pharmaceutically acceptable salt thereof.

4. A compound according to Claim 2 of the formula



wherein

$R_1$ ,  $R_2$ ,  $L$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$  and  $Q$  have meanings as defined in Claim 2;  
or a pharmaceutically acceptable salt thereof.

5. A compound according to Claim 4 wherein

$R_1$  is  $-\text{CH}_2\text{-X}$ ,  $-\text{O-X}$  or  $-\text{S-X}$ ; or

$R_1$  is  $-\text{NR}_8\text{-X}$ ,  $-\text{NR}_8\text{C(O)-X}$  or  $-\text{NR}_8\text{S(O)}_2\text{-X}$  in which  
 $R_8$  is hydrogen or lower alkyl; and

$X$  is  $-(\text{CH}_2)_m\text{-(CR}_9\text{R}_{10})_p\text{-(CH}_2)_n\text{-Z-W}$  in which

$m$  and  $n$  are independently zero or an integer of 1 or 2;

$p$  is zero or 1;

$R_9$  and  $R_{10}$  are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or

- 81 -

$R_9$  and  $R_{10}$  combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;

Z is a bond; or

Z is O,  $S(O)_{0-2}$ , or  $-NR_{11}-$  in which

$R_{11}$  is hydrogen or lower alkyl, provided that  $R_1$  is  $-CH_2-X$  when m, n and p are all zero;

W is aryl or heterocyclyl;

$R_2$  is hydrogen, halogen or hydroxy;

L is a bond;

$R_3$  is hydrogen or halogen;

$R_4$  is hydrogen, optionally substituted lower alkyl or aryl;

$R_5$  and  $R_6$  are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

$R_7$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

$R_7$  and  $R_6$  combined are O,  $S(O)_{0-2}$ ,  $-NR_{14}-$ ,  $-(CH_2)_{1-2}-$ ,  $-O-CH_2-$ ,  $-CH_2-O-$ ,  $-S(O)_{0-2}-CH_2-$ ,  $-CH_2-S(O)_{0-2}-$ ,  $-NR_{14}-CH_2-$ ,  $-CH_2-NR_{14}-$ ,  $-S(O)_{0-2}-NR_{14}-$  or  $-NR_{14}-S(O)_{0-2}-$  in which

$R_{14}$  is hydrogen or lower alkyl, provided  $R_6$  is located at the 2'-position;

Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or

Q combined with the atoms to which it is attached form a 9- to 10-membered bicyclic aromatic or heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

6. A compound according to Claim 5 wherein

$R_1$  is  $-CH_2-X$ ,  $-O-X$  or  $-S-X$ ; or

$R_1$  is  $-NR_8-X$ ,  $-NR_8C(O)-X$  or  $-NR_8S(O)_2-X$  in which

$R_8$  is hydrogen or lower alkyl; and

X is  $-(CH_2)_m-(CR_9R_{10})_p-(CH_2)_n-Z-W$  in which

- 82 -

m and n are independently zero or an integer of 1 or 2;

p is zero or 1;

R<sub>9</sub> and R<sub>10</sub> are independently hydrogen or lower alkyl; or

Z is a bond; or

Z is O, S(O)<sub>0-2</sub>, or -NR<sub>11</sub>- in which

R<sub>11</sub> is hydrogen or lower alkyl, provided that R<sub>1</sub> is -CH<sub>2</sub>-X when m, n and p are all zero;

W is aryl or heterocyclyl;

R<sub>2</sub> is hydrogen, halogen or hydroxy;

L is a bond;

R<sub>3</sub> is hydrogen or halogen;

R<sub>4</sub> is hydrogen;

R<sub>5</sub> and R<sub>6</sub> are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

R<sub>7</sub> is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

R<sub>7</sub> and R<sub>6</sub> combined are O, S(O)<sub>0-2</sub>, -NR<sub>14</sub>-, -(CH<sub>2</sub>)<sub>1-2</sub>-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-, -S(O)<sub>0-2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-S(O)<sub>0-2</sub>-, -NR<sub>14</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-NR<sub>14</sub>-, -S(O)<sub>0-2</sub>-NR<sub>14</sub>- or -NR<sub>14</sub>-S(O)<sub>0-2</sub>- in which

R<sub>14</sub> is hydrogen or lower alkyl, provided R<sub>6</sub> is located at the 2'-position;

Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or

Q combined with the atoms to which it is attached form a 9- to 10-membered bicyclic aromatic or heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

7. A compound according to Claim 6 wherein

R<sub>1</sub> is -NR<sub>8</sub>-X, -NR<sub>8</sub>C(O)-X or -NR<sub>8</sub>S(O)<sub>2</sub>-X in which

R<sub>8</sub> is hydrogen or lower alkyl;

or a pharmaceutically acceptable salt thereof.

8. A compound according to Claim 6 wherein

Q combined with the carbon atoms to which it is attached form a pyridyl or pyrimidinyl ring;


or a pharmaceutically acceptable salt thereof.

9. A compound according to Claim 6 wherein

Q combined with the carbon atoms to which it is attached form a thienyl, furyl, pyrrolyl or indolyl ring;

or a pharmaceutically acceptable salt thereof.

10. A compound according to Claim 5 of the formula



wherein

R<sub>1</sub> is -CH<sub>2</sub>-X, -O-X or -S-X; or

R<sub>1</sub> is -NR<sub>8</sub>-X, -NR<sub>8</sub>C(O)-X or -NR<sub>8</sub>S(O)<sub>2</sub>-X in which

R<sub>8</sub> is hydrogen or lower alkyl; and

X is -(CH<sub>2</sub>)<sub>m</sub>-(CR<sub>9</sub>R<sub>10</sub>)<sub>p</sub>-(CH<sub>2</sub>)<sub>n</sub>-Z-W in which

m, n and p are independently zero or 1;

R<sub>9</sub> is hydrogen;

R<sub>10</sub> is hydrogen or lower alkyl;

Z is a bond; or

Z is O, S(O)<sub>0-2</sub>, or -NR<sub>11</sub>- in which

R<sub>11</sub> is hydrogen or lower alkyl, provided that R<sub>1</sub> is -CH<sub>2</sub>-X when m, n and p are all zero;

W is aryl or heterocyclyl;



- 84 -

$R_2$  is hydrogen;

$R_3$  is hydrogen or halogen;

$R_5$  and  $R_6$  are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

$R_7$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

$R_7$  and  $R_8$  combined are O,  $S(O)_{0-2}$ ,  $-NR_{14}-$ ,  $-(CH_2)_{1-2}-$ ,  $-O-CH_2-$ ,  $-CH_2-O-$ ,  $-S(O)_{0-2}-CH_2-$ ,  $-CH_2-S(O)_{0-2}-$ ,  $-NR_{14}-CH_2-$ ,  $-CH_2-NR_{14}-$ ,  $-S(O)_{0-2}-NR_{14}-$  or  $-NR_{14}-S(O)_{0-2}-$  in which

$R_{14}$  is hydrogen or lower alkyl, provided  $R_6$  is located at the 2'-position;

$R_{15}$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

or a pharmaceutically acceptable salt thereof.

11. A compound according to Claim 10 wherein

$R_1$  is  $-O-X$  or  $-S-X$ ; and

$X$  is  $-(CH_2)_m-(CR_9R_{10})_p-(CH_2)_n-Z-W$  in which

$m$  is 1;

$n$  and  $p$  are zero;

$Z$  is a bond;

$W$  is aryl or heterocyclyl;

$R_3$  is hydrogen or halogen;

$R_5$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

$R_6$  is hydrogen;

$R_7$  is hydrogen;

$R_{15}$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

or a pharmaceutically acceptable salt thereof.

12. A compound according to Claim 11 wherein

$R_3$  is hydrogen;

or a pharmaceutically acceptable salt thereof.

13. A compound according to Claim 12 wherein

W is monocyclic aryl;

or a pharmaceutically acceptable salt thereof.


14. A compound according to Claim 5 wherein

p is 1;

$R_9$  and  $R_{10}$  combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;

or a pharmaceutically acceptable salt thereof.

15. A compound according to Claim 14 of the formula



wherein

$R_1$  is  $-\text{CH}_2\text{-X}$ ,  $-\text{O-X}$  or  $-\text{S-X}$ ; or

$R_1$  is  $-\text{NR}_8\text{-X}$ ,  $-\text{NR}_8\text{C(O)-X}$  or  $-\text{NR}_8\text{S(O)}_2\text{-X}$  in which

$R_8$  is hydrogen or lower alkyl; and

X is  $-(\text{CH}_2)_m\text{-CR}_9\text{R}_{10}\text{-(CH}_2)_n\text{-Z-W}$  in which

m and n are 1;

Z is a bond; or

Z is O,  $\text{S(O)}_{0-2}$ , or  $-\text{NR}_{11}-$  in which

$R_{11}$  is hydrogen or lower alkyl, provided that  $R_1$  is  $-\text{CH}_2\text{-X}$  when m, n and p are all zero;

W is aryl or heterocyclyl;

$R_2$  is hydrogen;

$R_3$  is hydrogen or halogen;

$R_5$  and  $R_6$  are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

$R_7$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

$R_7$  and  $R_8$  combined are O,  $S(O)_{0-2}$ ,  $-NR_{14}-$ ,  $-(CH_2)_{1-2}-$ ,  $-O-CH_2-$ ,  $-CH_2-O-$ ,  $-S(O)_{0-2}-CH_2-$ ,  $-CH_2-S(O)_{0-2}-$ ,  $-NR_{14}-CH_2-$ ,  $-CH_2-NR_{14}-$ ,  $-S(O)_{0-2}-NR_{14}-$  or  $-NR_{14}-S(O)_{0-2}-$  in which

$R_{14}$  is hydrogen or lower alkyl, provided  $R_6$  is located at the 2'-position;

$R_{15}$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

or a pharmaceutically acceptable salt thereof.

16. A compound of claim 15 wherein

$R_1$  is  $-O-X$  or  $-S-X$ ; and

$X$  is  $-CH_2-CR_9R_{10}-CH_2-Z-W$  in which

$Z$  is a bond;

$W$  is aryl;

$R_3$  is hydrogen;

$R_5$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

$R_6$  is hydrogen;

$R_7$  is hydrogen;

$R_{15}$  is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

or a pharmaceutically acceptable salt thereof.

17. A method for the inhibition of renin activity in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

18. A method for the prevention and/or treatment of conditions associated with renin activity in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.
19. A method according to Claim 18, which method comprises administering said compound in combination with a therapeutically effective amount of an anti-diabetic agent, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent.
20. A method for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders, which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.
21. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with one or more pharmaceutically acceptable carriers.
22. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a therapeutically effective amount of an anti-diabetic agents, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent.
23. A pharmaceutical composition according to Claim 21 or 22 for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
24. A pharmaceutical composition according to Claim 21 or 22, for use as medicament.

25. Use of a pharmaceutical composition according to Claim 21 or 22, for the preparation of a medicament for the treatment of conditions associated with renin activity.
26. Use of a compound according to Claim 1, for the preparation of a pharmaceutical composition for the treatment of conditions associated with renin activity.
27. Use according to Claim 25 or 26, wherein the condition associated with renin activity is selected from hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
28. A compound according to Claim 1, for use as a medicament.